CAM
AVNR

Capstone Asset Management’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Capstone Asset Management’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-10,091
Closed -$34K – 1845
2013
Q4 		$34K Sell
10,091
-5,540
-35% -$22.9K ﹤0.01% 1858
2013
Q3 		$66K Hold
15,631
– – ﹤0.01% 1973
2013
Q2 		$72K Buy
+15,631
New +$53.7K ﹤0.01% 1921

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capstone Asset Management's AVNR Position: Q1 2014 in Review

Capstone Asset Management sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2014, closing a stake of 10,091 shares — an estimated $34K sold.

Capstone Asset Management first reported a position in AVNR in Q2 2013 and held it in 3 quarters. The position peaked at $72K in Q2 2013. 100 funds tracked by Wall St. Rank hold AVNR as of Q1 2014.

  • Capstone Asset Management reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2014 after selling out during the quarter.
  • Capstone Asset Management sold 10,091 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2014, an estimated $34K.
  • Capstone Asset Management first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 3 quarters.
  • Capstone Asset Management's AVANIR PHARMACEUTICALS, INC CL A position peaked at $72K in Q2 2013.
  • 100 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2014.

Based on Capstone Asset Management's 13F filing for Q1 2014, filed 22 Apr 2014.